297 related articles for article (PubMed ID: 33975862)
21. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Hamid O; Ilaria R; Garbe C; Wolter P; Maio M; Hutson TE; Arance A; Lorigan P; Lee J; Hauschild A; Mohr P; Hahka-Kemppinen M; Kaiser C; Turner PK; Conti I; Grob JJ
Cancer; 2014 Jul; 120(13):2016-24. PubMed ID: 24676877
[TBL] [Abstract][Full Text] [Related]
22. Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Movva S; Verschraegen CF; Rabinowitz I; Mangalik A; Parks V; Lee FC
Melanoma Res; 2011 Feb; 21(1):76-9. PubMed ID: 21169871
[TBL] [Abstract][Full Text] [Related]
23. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
Kottschade LA; Suman VJ; Amatruda T; McWilliams RR; Mattar BI; Nikcevich DA; Behrens R; Fitch TR; Jaslowski AJ; Markovic SN
Cancer; 2011 Apr; 117(8):1704-10. PubMed ID: 21472717
[TBL] [Abstract][Full Text] [Related]
24. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
25. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
26. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
[TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Plummer R; Ghielmini M; Calvert P; Voi M; Renard J; Gallant G; Gupta E; Calvert H; Sessa C
Clin Cancer Res; 2002 Sep; 8(9):2788-97. PubMed ID: 12231518
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma.
Nathan FE; Berd D; Sato T; Mastrangelo MJ
Cancer; 2000 Jan; 88(1):79-87. PubMed ID: 10618609
[TBL] [Abstract][Full Text] [Related]
29. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
Gasparini G; Meo S; Comella G; Stani SC; Mariani L; Gamucci T; Avallone A; Lo Vullo S; Mansueto G; Bonginelli P; Gattuso D; Gion M
Cancer J; 2005; 11(3):209-16. PubMed ID: 16053664
[TBL] [Abstract][Full Text] [Related]
30. Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01).
Ngoi NYL; Heong V; Tang JI; Choo BA; Kumarakulasinghe NB; Lim D; Low M; Lim SE; Lim YW; Leong YH; Tseng M; Tong PSY; Ilancheran A; Low JJH; Ng J; Thian YL; Koh V; Tan DSP
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):701-711. PubMed ID: 33045316
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
[TBL] [Abstract][Full Text] [Related]
32. Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
Jones RJ; Hussain SA; Protheroe AS; Birtle A; Chakraborti P; Huddart RA; Jagdev S; Bahl A; Stockdale A; Sundar S; Crabb SJ; Dixon-Hughes J; Alexander L; Morris A; Kelly C; Stobo J; Paul J; Powles T
J Clin Oncol; 2017 Jun; 35(16):1770-1777. PubMed ID: 28402747
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
Fruehauf JP; El-Masry M; Osann K; Parmakhtiar B; Yamamoto M; Jakowatz JG
Cancer Chemother Pharmacol; 2018 Aug; 82(2):353-360. PubMed ID: 29943192
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study.
Hayashi RJ; Blaney S; Sullivan J; Weitman S; Vietti T; Bernstein ML;
J Pediatr Hematol Oncol; 2003 Jul; 25(7):539-42. PubMed ID: 12847320
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Homsi J; Bedikian AY; Kim KB; Papadopoulos NE; Hwu WJ; Mahoney SL; Hwu P
Melanoma Res; 2009 Aug; 19(4):238-42. PubMed ID: 19521262
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
37. A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Pishvaian MJ; Slack R; Koh EY; Beumer JH; Hartley ML; Cotarla I; Deeken J; He AR; Hwang J; Malik S; Firozvi K; Liu M; Elston B; Strychor S; Egorin MJ; Marshall JL
Cancer Chemother Pharmacol; 2012 Dec; 70(6):843-53. PubMed ID: 23014737
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Masters GA; Brockstein BE; Mani S; Ratain MJ
Med Oncol; 2003; 20(1):7-12. PubMed ID: 12665678
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
Stinchcombe TE; Socinski MA; Walko CM; O'Neil BH; Collichio FA; Ivanova A; Mu H; Hawkins MJ; Goldberg RM; Lindley C; Dees EC
Cancer Chemother Pharmacol; 2007 Oct; 60(5):759-66. PubMed ID: 17285317
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
